Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $16

Bicara Therapeutics Inc. +0.33%

Bicara Therapeutics Inc.

BCAX

24.01

+0.33%

Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ: BCAX) with a Equal-Weight and raises the price target from $11 to $16.